Home » Interviews » INTERVIEW: Avacta Group – 2019 is all about Milestones and Commercial Deals
Avacta Group

INTERVIEW: Avacta Group – 2019 is all about Milestones and Commercial Deals

Avacta Group plc (LON: AVCT) CEO Alastair Smith joins DirectorsTalk to discuss the latest update to the market. Alastair talks us through the highlights, provides us with some details around the appointment of Dr Jose Saro, expands on excising of options from Moderna and gives us an idea of what to look out for over the coming months.

 

Avacta Group plc’s principal focus is on its proprietary Affimer® technology which is a novel engineered alternative to antibodies that has wide application in Life Sciences for diagnostics, therapeutics and general research and development.

Antibodies dominate markets worth in excess of $100bn despite their shortcomings. Affimer® technology has been designed to address many of these negative performance issues, principally; the time taken to generate new antibodies, the reliance on an animal’s immune response, poor specificity in many cases, and batch to batch variability. Affimer® technology is based on a small protein that can be quickly generated to bind with high specificity and affinity to a wide range of protein targets.

Avacta has a pre-clinical biotech development programme with an in-house focus on immuno-oncology as well as partnered development programmes. Avacta is commercialising non-therapeutic Affimer® reagents through licensing to developers of life sciences research tools and diagnostics.